Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FGFR1 over exp |
| Therapy | Sorafenib |
| Indication/Tumor Type | renal cell carcinoma |
| Response Type | not applicable |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR1 over exp | renal cell carcinoma | not applicable | Sorafenib | Phase II | Emerging | In a clinical analysis of a Phase II trial, high Fgfr1 expression level was associated with decreased progression free survival in renal cell carcinoma patients treated with Nexavar (sorafenib) (PMID: 25900027). | 25900027 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (25900027) | The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma. | Full reference... |